Calidi BiotherapeuticsCLDI -4.19%12 Cash Ratio is 1.73 as of Mar. 2026, which is 811% above its 10-year median of 0.19. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, Calidi Biotherapeutics ranks worse than 62.65% on this metric.
Calidi Biotherapeutics has a Cash Ratio of 1.73. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Calidi Biotherapeutics's Cash Ratio or its related term are showing as below:
CLDI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.19 Max: 2
Current: 1.73
During the past 6 years, Calidi Biotherapeutics's highest Cash Ratio was 2.00. The lowest was 0.01. And the median was 0.19.
CLDI's Cash Ratio is ranked worse than 62.65% of 1387
companies
in the Biotechnology industry
Industry Median: 2.93
vs CLDI: 1.73
Calidi Biotherapeutics (AMEX:CLDI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Calidi Biotherapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a Cash Ratio of 1.73 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Calidi Biotherapeutics and its competitors. This is 811% above median its historical median of 0.19. Over the past decade, Calidi Biotherapeutics' Cash Ratio has ranged from 0.01 to 2.00. According to the industry distribution chart, Calidi Biotherapeutics ranks #869 out of 1387 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Calidi Biotherapeutics' Cash Ratio too high?
Calidi Biotherapeutics' current Cash Ratio of 1.73 is 811% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.00. The Biotechnology industry median Cash Ratio is 2.93. Calidi Biotherapeutics' value of 1.73 is 41% below this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #869 out of 1387 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Cash Ratio compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #869 out of 1387 companies for Cash Ratio. This places Calidi Biotherapeutics in the lower half of its industry. The industry median Cash Ratio is 2.93. Calidi Biotherapeutics' value of 1.73 is 41% below this benchmark. Historically, Calidi Biotherapeutics' own Cash Ratio has ranged from 0.01 to 2.00 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 2.93, Calidi Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,387 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current Cash Ratio of 1.73 is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Cash Ratio is 1.73, which is 811% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Cash Ratio of 1.73. The current Cash Ratio is 1.73, which is 811% above median its 10-year median of 0.19 and 41% below the Biotechnology industry median of 2.93. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Cash Ratio is 1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
